AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...

Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly ...

Pharmaceutical corporations Eli Lilly, Novo Nordisk, and Sanofi have been challenged by Doctors Without Borders to take ...

With a reduction in borrowing costs and consequent availability of cheaper capital, drugmakers can ramp up their R&D spending ...

French drugmaker Sanofi has confirmed its plan to spend €1.3bn on an insulin factory at its site near Frankfurt, website ...

AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...

Two big rivals in diabetes, Sanofi and Novo Nordisk, are promoting new 2-in-1 combination treatments for patients who fail to control their condition with insulin or oral drugs. Novo Nordisk’s ...

medication regimens and sensor devices. Despite its leadership in pharmaceutical products for diabetes, Sanofi is not a market leader in blood glucose meters and devices, with firms such as Abbott ...

Novo Nordisk's decision to stop insulin pen production poses a serious challenge to diabetes care in South Africa, where ...